German
|
English
|
French
Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "L04AG" (12)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Natalizumab (L04AG03) 2 products
WHO-DDD
L
IP
Tyruko 300 mg / 15 ml
1083.67
1194.95
10 %
Concentrate for infusion: Natalizumabum 300mg / 15ml
Sandoz
Pharmaceuticals AG
B / SL / SG
FB
G
L
IP
Tysabri 150 mg/ml
2
1548.10
1700.05
10 %
Injection solution in prefilled syringe: Natalizumabum 150 mg/ml
Biogen Switzerland AG
B / SL
FB
G
Vedolizumab (L04AG05) 2 products
WHO-DDD
L
IP
CI
Entyvio subkutan 108 mg
544.26
608.35
10 %
Injection solution in prefilled syringe: Vedolizumabum 108mg / 0.68ml
Takeda Pharma AG
A / SL
FB
G
L
IP
CI
Entyvio subkutan 108 mg
544.26
608.35
10 %
Injektionslösung in einem Fertigpen: Vedolizumabum 108mg / 0.68ml
Takeda Pharma AG
A / SL
FB
G
Ocrelizumab (L04AG08) 2 products
WHO-DDD
L
IP
Ocrevus subkutan 920
mg/23 ml
9264.92
9813.60
10 %
Injection solution: Ocrelizumabum 920mg / 23ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
L
IP
Ocrevus
4632.46
5054.50
10 %
Concentrate for infusion: Ocrelizumabum 300mg / 10ml
Roche Pharma
(Schweiz) AG
A / SL
FB
G
Anifrolumab (L04AG11) 3 products
WHO-DDD
L
IP
Saphnelo 300 mg/2 ml
895.73
990.60
10 %
Concentrate for infusion: Anifrolumabum 300mg / 2ml
AstraZeneca AG
A / SL
FB
G
L
IP
CI
Saphnelo 120 mg/0.8 ml
223.93
259.95
10 %
Injektionslösung in einem Fertigpen: Anifrolumabum 120mg / 0.8ml
AstraZeneca AG
B / SL
FB
G
L
IP
CI
Saphnelo 120 mg/0.8 ml
4
895.73
990.60
10 %
Injektionslösung in einem Fertigpen: Anifrolumabum 120mg / 0.8ml
AstraZeneca AG
B / SL
FB
G
Ofatumumab (L04AG12) 1 products
WHO-DDD
L
IP
CI
Kesimpta
1139.39
1255.55
10 %
Injektionslösung in Fertigpen: Ofatumumabum 20mg / 0.4ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
Ublituximab (L04AG14) 2 products
WHO-DDD
L
IP
Briumvi 25 mg/ml
2106.69
2307.55
10 %
Concentrate for infusion: Ublituximabum 150mg / 6ml
Neuraxpharm
Switzerland AG
A / SL
FB
G
L
IP
Briumvi 25 mg/ml
3
6320.07
6792.20
10 %
Concentrate for infusion: Ublituximabum 150mg / 6ml
Neuraxpharm
Switzerland AG
A / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home
